Ammar Chaudhry

Step inside a candid, forward-looking conversation with the field’s scientific leaders as they dissect what the data has – and hasn’t – told us about radiopharmaceuticals heading into 2026. Challenge

assumptions, explore inflection points, and put your questions directly to the experts shaping the next wave of innovation, regulation, and clinical design

• Which scientific assumptions about radiopharmaceutical behavior have held up under clinical data through 2026 – and which are now clearly incomplete or wrong?
• Are current pharmacokinetic and dosimetry models sufficiently predictive for decision-making, or are we still over-relying on empirical iteration in the clinic?
• What is needed in the field to continue investment and movement?
• What lessons from recent late-stage programs should be influencing how we design first-in-human studies today?
• Does existing regulatory paradigms adequately reflect the unique risk–benefit calculus of radiopharmaceuticals, or is misalignment now a rate-limiting step?
• Which manufacturing and supply-chain constraints are a fundamentally scientific problem – and which require more infrastructural changes?
• Looking ahead, what scientific bottleneck is most likely to determine winners and failures in radiopharmaceuticals beyond 2026?